From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors

Koravovic, Mladen; Mayasundari, Anand; Tasic, Gordana; Keramatnia, Fatemeh; Stachowski, Timothy R.; Cui, Huarui; Chai, Sergio C.; Jonchere, Barbara; Yang, Lei; Li, Yong; Fu, Xiang; Hiltenbrand, Ryan; Paul, Leena; Mishra, Vibhor; Klco, Jeffery M.; Roussel, Martine F.; Pomerantz, William CK.; Fischer, Marcus; Rankovic, Zoran; Savic, Vladimir

doi:10.1016/j.ejmech.2023.115246

From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors

Journal Article · Sat Mar 04 00:00:00 EST 2023 · European Journal of Medicinal Chemistry

DOI:https://doi.org/10.1016/j.ejmech.2023.115246· OSTI ID:2423439

Koravovic, Mladen ^[1]; Mayasundari, Anand ^[2]; Tasic, Gordana ^[1]; Keramatnia, Fatemeh ^[2]; Stachowski, Timothy R. ^[2]; Cui, Huarui ^[3]; Chai, Sergio C. ^[2]; Jonchere, Barbara ^[2]; Yang, Lei ^[2]; Li, Yong ^[2]; Fu, Xiang ^[2]; Hiltenbrand, Ryan ^[2]; Paul, Leena ^[2]; Mishra, Vibhor ^[2]; Klco, Jeffery M. ^[2]; Roussel, Martine F. ^[2]; Pomerantz, William CK. ^[3]; Fischer, Marcus ^[2]; Rankovic, Zoran ^[2]; Savic, Vladimir ^[1]

Univ. of Belgrade (Serbia)
St. Jude Children's Research Hospital, Memphis, TN (United States)
Univ. of Minnesota, Minneapolis, MN (United States)

An X-ray structure of a CLICK chemistry-based BET PROTAC bound to BRD2(BD2) inspired synthesis of JQ1 derived heterocyclic amides. This effort led to the discovery of potent BET inhibitors displaying overall improved profiles when compared to JQ1 and birabresib. A thiadiazole derived 1q (SJ1461) displayed excellent BRD4 and BRD2 affinity and high potency in the panel of acute leukaemia and medulloblastoma cell lines. A structure of 1q co-crystalised with BRD4-BD1 revealed polar interactions with the AZ/BC loops, in particular with Asn140 and Tyr139, rationalising the observed affinity improvements. In addition, exploration of pharmacokinetic properties of this class of compounds suggest that the heterocyclic amide moiety improves drug-like features. Finally, our study led to the discovery of potent and orally bioavailable BET inhibitor 1q (SJ1461) as a promising candidate for further development.

View Accepted Manuscript (DOE)

Research Organization:: Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: USDOE Office of Science (SC), Basic Energy Sciences (BES)

Grant/Contract Number:: AC02-06CH11357

OSTI ID:: 2423439

Journal Information:: European Journal of Medicinal Chemistry, Journal Name: European Journal of Medicinal Chemistry Vol. 251; ISSN 0223-5234

Publisher:: ElsevierCopyright Statement

Country of Publication:: United States

Language:: English

References (44)

Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs Min, Jaeki; Mayasundari, Anand; Keramatnia, Fatemeh Angewandte Chemie International Edition, Vol. 60, Issue 51 https://doi.org/10.1002/anie.202108848	journal	November 2021
Plasma protein binding: From discovery to development Bohnert, Tonika; Gan, Liang-Shang Journal of Pharmaceutical Sciences, Vol. 102, Issue 9 https://doi.org/10.1002/jps.23614	journal	September 2013
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives Feng, Lu; Wang, Guan; Chen, Yi Medicinal Research Reviews, Vol. 42, Issue 2 https://doi.org/10.1002/med.21859	journal	October 2021
Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases Padmanabhan, Balasundaram; Mathur, Shruti; Manjula, Ramu Journal of Biosciences, Vol. 41, Issue 2 https://doi.org/10.1007/s12038-016-9600-6	journal	April 2016
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W. Advanced Drug Delivery Reviews, Vol. 64 https://doi.org/10.1016/j.addr.2012.09.019	journal	December 2012
Bromodomains: Structure, function and pharmacology of inhibition Ferri, Elena; Petosa, Carlo; McKenna, Charles E. Biochemical Pharmacology, Vol. 106 https://doi.org/10.1016/j.bcp.2015.12.005	journal	April 2016
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy Hoshi, Ayako; Sakamoto, Takeshi; Takayama, Jun Bioorganic & Medicinal Chemistry, Vol. 24, Issue 13 https://doi.org/10.1016/j.bmc.2016.05.010	journal	July 2016
BET bromodomain inhibitors Schwalm, Martin P.; Knapp, Stefan Current Opinion in Chemical Biology, Vol. 68 https://doi.org/10.1016/j.cbpa.2022.102148	journal	June 2022
Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins Fu, Yuantao; Zhang, Yanzhi; Sun, Haiying European Journal of Medicinal Chemistry, Vol. 226 https://doi.org/10.1016/j.ejmech.2021.113853	journal	December 2021
A common binding motif in the ET domain of BRD3 forms polymorphic structural interfaces with host and viral proteins Aiyer, Sriram; Swapna, G. V. T.; Ma, Li-Chung Structure, Vol. 29, Issue 8 https://doi.org/10.1016/j.str.2021.01.010	journal	August 2021
Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation Huang, Yifan; Yokoe, Hiromasa; Kaiho-Soma, Ai Bioconjugate Chemistry, Vol. 33, Issue 1 https://doi.org/10.1021/acs.bioconjchem.1c00490	journal	December 2021
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development Chen, Juncheng; Tang, Pan; Wang, Yuxi Journal of Medicinal Chemistry, Vol. 65, Issue 7 https://doi.org/10.1021/acs.jmedchem.1c01835	journal	March 2022
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors Romero, F. Anthony; Taylor, Alexander M.; Crawford, Terry D. Journal of Medicinal Chemistry, Vol. 59, Issue 4 https://doi.org/10.1021/acs.jmedchem.5b01514	journal	April 2015
A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation Wurz, Ryan P.; Dellamaggiore, Ken; Dou, Hannah Journal of Medicinal Chemistry, Vol. 61, Issue 2 https://doi.org/10.1021/acs.jmedchem.6b01781	journal	April 2017
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds Chan, Kwok-Ho; Zengerle, Michael; Testa, Andrea Journal of Medicinal Chemistry, Vol. 61, Issue 2 https://doi.org/10.1021/acs.jmedchem.6b01912	journal	May 2017
Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins Ohoka, Nobumichi; Tsuji, Genichiro; Shoda, Takuji ACS Chemical Biology, Vol. 14, Issue 12 https://doi.org/10.1021/acschembio.9b00704	journal	October 2019
Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications Henning, Nathaniel J.; Manford, Andrew G.; Spradlin, Jessica N. Journal of the American Chemical Society, Vol. 144, Issue 2 https://doi.org/10.1021/jacs.1c03980	journal	January 2022
Light-Induced Protein Degradation with Photocaged PROTACs Xue, Gang; Wang, Kun; Zhou, Danli Journal of the American Chemical Society, Vol. 141, Issue 46 https://doi.org/10.1021/jacs.9b06422	journal	September 2019
Parallel Artificial Membrane Permeability Assay: A New Membrane for the Fast Prediction of Passive Human Skin Permeability Ottaviani, Giorgio; Martel, Sophie; Carrupt, Pierre-Alain Journal of Medicinal Chemistry, Vol. 49, Issue 13 https://doi.org/10.1021/jm060230+	journal	May 2006
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design Meanwell, Nicholas A. Journal of Medicinal Chemistry, Vol. 54, Issue 8 https://doi.org/10.1021/jm1013693	journal	April 2011
Selective inhibition of BET bromodomains Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah Nature, Vol. 468, Issue 7327 https://doi.org/10.1038/nature09504	journal	September 2010
PROTACs: great opportunities for academia and industry Sun, Xiuyun; Gao, Hongying; Yang, Yiqing Signal Transduction and Targeted Therapy, Vol. 4, Issue 1 https://doi.org/10.1038/s41392-019-0101-6	journal	December 2019
Achieving clinical success with BET inhibitors as anti-cancer agents Shorstova, Tatiana; Foulkes, William D.; Witcher, Michael British Journal of Cancer, Vol. 124, Issue 9 https://doi.org/10.1038/s41416-021-01321-0	journal	March 2021
PROTAC targeted protein degraders: the past is prologue Békés, Miklós; Langley, David R.; Crews, Craig M. Nature Reviews Drug Discovery, Vol. 21, Issue 3 https://doi.org/10.1038/s41573-021-00371-6	journal	January 2022
Structure and acetyl-lysine recognition of the bromodomain Mujtaba, S.; Zeng, L.; Zhou, M-M Oncogene, Vol. 26, Issue 37 https://doi.org/10.1038/sj.onc.1210618	journal	August 2007
PROTACs: past, present and future Li, Ke; Crews, Craig M. Chemical Society Reviews, Vol. 51, Issue 12 https://doi.org/10.1039/D2CS00193D	journal	January 2022
PROTAC degraders as chemical probes for studying target biology and target validation Němec, Václav; Schwalm, Martin P.; Müller, Susanne Chemical Society Reviews, Vol. 51, Issue 18 https://doi.org/10.1039/D2CS00478J	journal	January 2022
Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction Crowe, Brandon L.; Larue, Ross C.; Yuan, Chunhua Proceedings of the National Academy of Sciences, Vol. 113, Issue 8 https://doi.org/10.1073/pnas.1516813113	journal	February 2016
Structural Basis for Acetylated Histone H4 Recognition by the Human BRD2 Bromodomain Umehara, Takashi; Nakamura, Yoshihiro; Jang, Moon Kyoo Journal of Biological Chemistry, Vol. 285, Issue 10 https://doi.org/10.1074/jbc.M109.062422	journal	March 2010
Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system Werner, Michael T.; Wang, Hongxin; Hamagami, Nicole Journal of Biological Chemistry, Vol. 295, Issue 7 https://doi.org/10.1074/jbc.RA119.010679	journal	February 2020
Histone acetylation in gene regulation Verdone, L. Briefings in Functional Genomics and Proteomics, Vol. 5, Issue 3 https://doi.org/10.1093/bfgp/ell028	journal	May 2006
Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes† Li, Feng; MacKenzie, Kevin R.; Jain, Prashi Biology of Reproduction, Vol. 103, Issue 2 https://doi.org/10.1093/biolre/ioaa043	journal	April 2020
Histone acetylation and transcriptional regulatory mechanisms Struhl, K. Genes & Development, Vol. 12, Issue 5 https://doi.org/10.1101/gad.12.5.599	journal	March 1998
Phthalimide conjugation as a strategy for in vivo target protein degradation Winter, G. E.; Buckley, D. L.; Paulk, J. Science, Vol. 348, Issue 6241 https://doi.org/10.1126/science.aab1433	journal	May 2015
Targeting BET Bromodomains in Cancer Trojer, Patrick Annual Review of Cancer Biology, Vol. 6, Issue 1 https://doi.org/10.1146/annurev-cancerbio-070120-103531	journal	April 2022
BET Proteins as Targets for Anticancer Treatment Stathis, Anastasios; Bertoni, Francesco Cancer Discovery, Vol. 8, Issue 1 https://doi.org/10.1158/2159-8290.CD-17-0605	journal	December 2017
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor Ozer, Hatice Gulcin; El-Gamal, Dalia; Powell, Ben Cancer Discovery, Vol. 8, Issue 4 https://doi.org/10.1158/2159-8290.CD-17-0902	journal	April 2018
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors Lewin, Jeremy; Soria, Jean-Charles; Stathis, Anastasios Journal of Clinical Oncology, Vol. 36, Issue 30 https://doi.org/10.1200/JCO.2018.78.2292	journal	October 2018
Targeting BET bromodomain proteins in solid tumors Sahai, Vaibhav; Redig, Amanda J.; Collier, Katharine A. Oncotarget, Vol. 7, Issue 33 https://doi.org/10.18632/oncotarget.9804	journal	June 2016
In Vivo-In Vitro-In Silico Pharmacokinetic Modelling in Drug Development Pelkonen, Olavi; Turpeinen, Miia; Raunio, Hannu Clinical Pharmacokinetics, Vol. 50, Issue 8 https://doi.org/10.2165/11592400-000000000-00000	journal	August 2011
Childhood and adolescent cancer statistics, 2014: Cancer in Children and Adolescents Ward, Elizabeth; DeSantis, Carol; Robbins, Anthony CA: A Cancer Journal for Clinicians, Vol. 64, Issue 2 https://doi.org/10.3322/caac.21219	journal	January 2014
A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles Ali, Hafiz Akbar; Li, Yalan; Bilal, Akram Hafiz Muhammad Frontiers in Pharmacology, Vol. 13 https://doi.org/10.3389/fphar.2022.818891	journal	March 2022
The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins Taniguchi, Yasushi International Journal of Molecular Sciences, Vol. 17, Issue 11 https://doi.org/10.3390/ijms17111849	journal	November 2016
BET Proteins as Attractive Targets for Cancer Therapeutics Sarnik, Joanna; Popławski, Tomasz; Tokarz, Paulina International Journal of Molecular Sciences, Vol. 22, Issue 20 https://doi.org/10.3390/ijms222011102	journal	October 2021